CL SEC Filings

Colgate-Palmolive Co. (CL) filed an 8-K on May 13, 2026, detailing the results of its Annual Meeting of Stockholders held on May 8, 2026. The meeting primarily focused on routine governance matters. All incumbent directors standing for re-election were approved by a significant margin, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, the company's choice of PricewaterhouseCoopers LLP as its independent auditor for the upcoming fiscal year was overwhelmingly ratified. Shareholders also provided a non-binding advisory approval for the company's executive compensation. Importantly, two significant shareholder proposals, one concerning the removal of Diversity, Equity, and Inclusion (DEI) from board candidate considerations and another advocating for an independent board chairman, failed to gain majority support, suggesting that the current board's approach to these matters aligns with the majority of the company's voting shareholders.

Colgate-Palmolive Company (CL) has filed an 8-K report detailing its financial results for the quarter ended March 31, 2026, alongside an expanded productivity program. The press release, incorporated by reference, provides the earnings information investors will be focused on. A key development is the significant expansion of the "Strategic Growth and Productivity Program," originally approved in July 2025. The estimated cumulative pre-tax charges for this program have increased from a range of $200 million-$300 million to $350 million-$550 million. This expansion reflects a commitment to further operational alignment, supply chain optimization, and overhead cost reduction to support the company's 2030 strategy. The charges are primarily related to employee severance and termination benefits, with a smaller portion allocated to asset write-offs and other exit costs. While the majority of these charges are expected to be cash expenditures, the company emphasizes that substantially all will be incurred by the end of 2028. Investors should monitor the company's execution of this expanded program and its impact on future financial performance and cost efficiencies.

Colgate-Palmolive Company reported net sales of $5.324 billion for the three months ended March 31, 2026, an increase of 8.4% compared to the prior year's quarter. This growth was driven by a combination of volume increase, net selling price adjustments, and favorable foreign exchange rates, alongside a contribution from the Prime100 acquisition. Diluted earnings per share for the quarter were $0.80, a decrease from $0.85 in the same period last year, primarily impacted by charges related to the expanded Strategic Growth and Productivity Program. Excluding these program charges and other one-time items, adjusted earnings per share increased to $0.97. The company continues to navigate a challenging global environment characterized by geopolitical tensions and inflationary pressures. Despite these headwinds, Colgate-Palmolive is executing its 2030 strategy, focusing on organic sales growth, operational efficiencies, and effective capital allocation. The expansion of the Strategic Growth and Productivity Program, now expected to incur charges between $350-$550 million, aims to drive future growth and efficiency, with projected annualized pre-tax savings of $200-$300 million.

Colgate-Palmolive Company (CL) announced a significant leadership transition within its legal department. Jennifer M. Daniels, the long-serving Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. This departure marks the end of an era for a key executive who has guided the company's legal affairs for over a decade. In response to Ms. Daniels' upcoming retirement, the Board of Directors has elected Betsy Fishbone, currently the Executive Vice President and Deputy Chief Legal Officer, to succeed her as Chief Legal Officer and Secretary, effective June 1, 2026. To ensure a seamless handover and leverage Ms. Daniels' extensive experience, she will transition to the role of Vice Chair of the Company, also effective June 1, 2026. This move is designed to facilitate an orderly transition of responsibilities and maintain continuity in the company's legal leadership.

Colgate-Palmolive Company (CL) has announced a realignment of its reportable operating segments, effective for the first quarter of fiscal year 2026. This strategic move, part of its previously announced Strategic Growth and Productivity Program, aims to optimize operating scale and drive growth within its global markets. The primary change involves combining the Europe and Africa/Eurasia segments (with specific exclusions) and the Skin Health business into a new, consolidated 'Europe, Middle East and Africa' reportable operating segment. Furthermore, Russia and Belarus operations, previously under Africa/Eurasia, will now be reported within the Asia Pacific segment. Investors should note that this realignment is purely a reporting change and does not affect the Company's historical consolidated financial results, including operations, financial position, or cash flows. Colgate-Palmolive has provided recast historical segment data to facilitate comparison with the new structure.

Colgate-Palmolive Company (CL) has announced a significant change in its Board of Directors. Effective March 15, 2026, Dr. Christopher S. Boerner, currently the Board Chair and CEO of Bristol-Myers Squibb, will join the Colgate-Palmolive Board. Dr. Boerner's extensive experience in global business leadership, particularly within the biopharmaceutical and healthcare sectors, is expected to bring valuable expertise to the company's strategic direction. In conjunction with this appointment, Steven A. Cahillane has informed the Board that he will not seek reelection at the upcoming Annual Meeting of Stockholders on May 8, 2026. This decision is attributed to the increased demands of his new role as CEO of The Kraft Heinz Company. These board-level transitions signal a refresh in leadership perspective and potentially a strengthened focus on areas complementary to Colgate-Palmolive's existing business.

Colgate-Palmolive Company's 2025 Annual Report (10-K) highlights a year of resilience amidst challenging macroeconomic and geopolitical conditions. The company achieved a 1.4% increase in Net sales, driven primarily by a 2.1% increase in net selling prices, which helped offset a slight decline in volume. Organic sales growth was also 1.4%. The Oral, Personal, and Home Care segment saw modest growth, while the Pet Nutrition segment, bolstered by the acquisition of Prime100, also reported sales increases. Despite inflationary pressures and higher raw material costs impacting gross margins, Colgate-Palmolive demonstrated effective cost management through its funding-the-growth initiatives and implemented a new Strategic Growth and Productivity Program aimed at optimizing operations and reducing overhead. The company continues to focus on its 2030 strategy, emphasizing innovation, digital capabilities, and omnichannel demand generation. While net income and diluted EPS saw declines year-over-year due to significant impairment charges related to the skin health business and other one-time items, the underlying operational performance, excluding these items, showed modest growth.

Colgate-Palmolive Company (CL) has filed an 8-K report on January 30, 2026, to announce its financial results for the quarter and full year ended December 31, 2025. The core of this filing is the press release (Exhibit 99) containing these results, which provides investors with key performance metrics and financial condition updates. While the specific details of the earnings are not included in the 8-K text itself, this filing serves as the official notification and incorporation of that information by the company into its SEC disclosures.

Colgate-Palmolive Company (CL) has filed an 8-K report detailing a significant debt financing transaction. On November 3, 2025, the company entered into an underwriting agreement for the issuance and sale of €600,000,000 of 3.250% Senior Notes due 2035. This offering was made under the company's existing automatic shelf registration statement on Form S-3. These notes were issued on November 10, 2025, under an indenture dated November 15, 1992. The underwriting agreement includes standard provisions for representations, warranties, covenants, and indemnification from both the company and the underwriters. This filing provides transparency on the terms of the debt issuance and the associated legal documentation.

Colgate-Palmolive Company (CL) reported a slight increase in net sales for the third quarter of 2025, reaching $5.131 billion, a 2.0% rise compared to the prior year's period. This growth was primarily driven by net selling price increases and a positive foreign exchange impact, though it was partially offset by a decline in sales volume. Diluted Earnings Per Share (EPS) saw a modest increase to $0.91 from $0.90 year-over-year. The company experienced higher raw and packaging material costs, which led to a decrease in gross profit margin. Despite this pressure, Colgate-Palmolive implemented cost-saving initiatives and pricing strategies to mitigate the impact. The company also announced a new "Strategic Growth and Productivity Program" aimed at driving future growth and efficiencies, which is expected to incur pre-tax charges between $200 and $300 million over the next three years. Management remains focused on driving organic sales growth and operational efficiencies despite challenging global macroeconomic conditions.

Colgate-Palmolive Company (CL) filed an 8-K on October 31, 2025, reporting on its financial results for the quarter ended September 30, 2025, via an attached press release. Investors should note the company is also providing updates on its previously disclosed Strategic Growth and Productivity Program. This program, approved in July 2025, aims to enhance growth and support its 2030 strategy through organizational alignment, supply chain optimization, and cost reduction. The company anticipates cumulative pre-tax charges between $200 million and $300 million related to this program, with a significant portion (75% to 85%) expected to involve cash expenditures and substantially all charges incurred by the end of 2028. The charges are primarily composed of employee-related costs and asset-related charges, with a global distribution across various geographical segments and its Hill's Pet Nutrition business.

Colgate-Palmolive Company (CL) reported its financial results for the second quarter and first half of 2025. For the quarter, net sales increased by 1.0% to $5.11 billion, driven by net selling price increases, while volume remained flat. The Hill’s Pet Nutrition segment showed stronger growth at 3.8%, aided by the recent acquisition of Prime100. Diluted Earnings Per Share (EPS) saw an increase to $0.91 for the quarter. For the first six months, net sales saw a slight decrease of 1.0% to $10.02 billion, with organic sales growing 1.6% driven by price increases and a slight volume contribution from the Pet Nutrition segment. The company continues to manage through inflationary pressures and global economic uncertainties, implementing cost-saving initiatives and revenue growth management strategies.

Colgate-Palmolive Company (CL) has filed an 8-K report highlighting two key events. The first pertains to the release of their earnings for the second quarter ended June 30, 2025, as detailed in a press release attached as an exhibit. While specific financial figures from this press release are not detailed within the 8-K text itself, this filing serves as notification to investors about the availability of this crucial quarterly performance data. The second, and more significant, announcement details the approval of a new three-year "Productivity Program" by the Board of Directors. This program, effective immediately and extending through 2028, aims to enhance future growth by optimizing the global supply chain, streamlining organizational structure, and reducing overhead costs. The company anticipates cumulative pre-tax charges between $200 million and $300 million to be recognized over the program's duration, primarily recorded in the Corporate segment and not impacting internal segment operating performance metrics.

Colgate-Palmolive Company (CL) announced a significant executive appointment and a planned retirement, signaling strategic shifts in its leadership. The company has appointed Shane Grant as its new Chief Operating Officer, Americas, effective June 16, 2025. Mr. Grant brings extensive international experience from leadership roles at Danone and The Coca-Cola Company, most recently serving as Group Deputy CEO and CEO Americas at Danone. In addition, Prabha Parameswaran, currently Group President, Growth and Strategy, will transition to Vice Chair effective June 16, 2025, ahead of her planned retirement on October 1, 2025. The company has also made other executive promotions, including Panagiotis Tsourapas to Chief Operating Officer, Europe, Asia Pacific, Africa Eurasia, Skin Health & Global Customer Development, and John Hazlin to Chief Growth Officer, both effective June 16, 2025. These appointments suggest a focus on strengthening regional operations and driving global growth initiatives.

Colgate-Palmolive Company (CL) has filed an 8-K detailing the results of its Annual Meeting of Stockholders held on May 9, 2025. The meeting focused on routine corporate governance matters, including the election of directors, ratification of the independent auditor, and advisory votes on executive compensation and specific stockholder proposals. All incumbent directors proposed for re-election were overwhelmingly approved, indicating strong shareholder confidence in the current leadership and board composition. The company's choice of PricewaterhouseCoopers LLP as its auditor for the upcoming fiscal year was also ratified with substantial support.

Colgate-Palmolive Company (CL) has announced the successful issuance and sale of $500,000,000 aggregate principal amount of its 4.200% Senior Notes due 2030. This debt offering was completed under the Company's existing automatic shelf registration statement and was formalized through an underwriting agreement with Citigroup Global Markets Inc. and Scotia Capital (USA) Inc. as representatives of the underwriters. The issuance of these notes, which matures in 2030, is a standard capital markets transaction intended to support the company's ongoing operations and strategic initiatives. Investors should note that this 8-K filing primarily concerns the details of this debt issuance, including the underwriting agreement and the terms of the notes. While it does not disclose any new financial performance metrics or strategic shifts, it signals the company's proactive approach to managing its capital structure and securing funding. The fixed coupon rate of 4.200% provides a clear cost of debt for this issuance, and the transaction is subject to customary representations, warranties, and indemnification clauses.

Colgate-Palmolive Company reported first-quarter 2025 results with a slight decrease in net sales to $4.911 billion, down 3.1% from $5.065 billion in the prior year. This decline was primarily driven by a 4.4% negative impact from foreign exchange and a 0.1% volume decrease, partially offset by a 1.5% increase in net selling prices. On an organic basis (excluding foreign exchange, acquisitions, and divestitures), net sales grew by 1.4%. Diluted earnings per share increased to $0.85 from $0.83 in the prior year, showing a positive trend despite top-line pressure. The company experienced mixed performance across its segments, with Oral, Personal, and Home Care net sales decreasing 4.3% (though organic sales grew 1.0%), while Hill's Pet Nutrition saw a 1.5% increase in net sales (with organic sales up 2.9%). The company highlighted improvements in gross profit margin to 60.8% from 60.0%, driven by cost savings, pricing actions, and favorable mix, which helped to offset increased raw and packaging material costs. Management indicated continued focus on organic sales growth, operational efficiencies, and capital allocation, including increased dividends and a new share repurchase program.

Colgate-Palmolive Company (CL) has filed an 8-K report on April 24, 2025, to announce its financial results for the quarter ended March 31, 2025. The key details of these results are provided in a press release, attached as Exhibit 99, which is incorporated by reference into this filing. Investors should refer to this press release for specific financial performance metrics and management's commentary on the company's operational and financial condition during the period. While the 8-K itself is a standard notification of the earnings release, it does not contain the detailed financial tables or qualitative analysis. The press release serves as the primary source of information for investors seeking to understand Colgate-Palmolive's performance, including revenue, profitability, and any forward-looking statements or strategic updates. The filing also includes the standard Cover Page Interactive Data File.

Colgate-Palmolive Company's 2024 10-K filing highlights a year of solid growth driven by both volume and pricing strategies across its Oral, Personal, and Home Care, and Pet Nutrition segments. The company achieved net sales growth of 3.3% and an impressive organic sales increase of 7.4%, demonstrating resilience in a challenging global economic environment marked by inflation and geopolitical uncertainties. Key to this performance was the strategic focus on innovation, higher-growth segments, and expanding into faster-growing channels and markets. Gross profit margin saw a notable improvement due to cost savings initiatives and higher pricing, though partially offset by increased raw material costs. The company also emphasized its commitment to sustainability, making progress on its 2025 targets, including the transition to recyclable toothpaste tubes and investments in renewable energy. Despite ongoing global economic headwinds and competitive pressures, Colgate-Palmolive maintains a strong financial position, a clear business strategy focused on compounding earnings per share growth, and a commitment to returning value to shareholders through dividends and share repurchases.

Colgate-Palmolive Company (CL) has filed an 8-K report on January 31, 2025, to announce its financial results for the quarter and full year ended December 31, 2024. The core of this filing is the press release, incorporated by reference as Exhibit 99, which provides the detailed earnings information that investors will be looking to analyze. While the 8-K itself is brief, serving primarily as a notification and attachment of the earnings release, the press release contains the critical financial metrics such as revenue, earnings per share (EPS), and potentially guidance for the upcoming fiscal year. Investors should refer to the attached press release for specific performance figures and management commentary on the company's operational and financial condition.

This 8-K/A filing from Colgate-Palmolive (CL) serves as an amendment, primarily to provide updated financial reporting information and clarify segment reporting changes. The most significant update for investors relates to the earnings for the quarter ended September 30, 2024, as announced in a press release dated October 25, 2024. While the earnings details themselves are incorporated by reference via Exhibit 99.1, the filing confirms that this information has been officially communicated. Furthermore, the company has realigned its skin health business reporting structure, effective July 1, 2024. This change consolidates previously dispersed skin health operations into the North America reportable operating segment. It's crucial to note that this realignment, while affecting segment reporting, does not alter the company's overall consolidated financial results or position. The company has provided recast historical segment information (Exhibit 99.2) for consistency with the new structure, allowing investors to analyze performance on a comparable basis.

Colgate-Palmolive Company (CL) filed an 8-K on October 25, 2024, to announce its financial results for the quarter ended September 30, 2024. The core of the filing pertains to the earnings press release, which is incorporated by reference. While specific financial figures are not detailed within the 8-K text itself, investors should note that this filing serves as the official notification of these results, typically accompanied by detailed performance metrics, revenue, and profit figures discussed in the press release. Additionally, the company disclosed a change in its reporting structure for the skin health business, effective July 1, 2024. This change involves realigning the skin health business results from the Europe segment to the North America segment. Importantly, this realignment does not impact Colgate-Palmolive's consolidated financial results or position. The company has provided recast historical segment information to offer investors a consistent view under the new structure, which is included as an exhibit. Investors should consult the referenced press release (Exhibit 99.1) for the actual financial performance data and the recast segment information (Exhibit 99.2) for a clearer understanding of segment reporting going forward.

Colgate-Palmolive Company reported solid financial results for the nine months ended September 30, 2024, with net sales increasing by 4.5% to $15.2 billion and net income attributable to the company rising 36% to $2.15 billion. Diluted EPS also saw a significant increase to $2.61 from $1.90 in the prior year period. The company demonstrated strong organic sales growth of 8.5% for the nine-month period, driven by both volume and pricing strategies across its Oral, Personal and Home Care, and Pet Nutrition segments. Gross profit margin improved to 60.6% from 57.7% in the prior year, reflecting cost savings and pricing actions, though partially offset by higher raw material costs. The company continues to navigate a challenging macroeconomic environment characterized by inflation and foreign currency volatility, particularly in hyper-inflationary economies. Despite these headwinds, Colgate-Palmolive maintained its market share in global toothpaste and manual toothbrush categories. The company's strategic focus on innovation, efficiency through its "funding-the-growth" initiatives, and investment in brands positions it for continued resilience and growth, even amidst global economic uncertainties and increased competition.

Colgate-Palmolive Company (CL) reported robust financial results for the second quarter and first half of 2024, demonstrating strong top-line growth driven by both volume and pricing. For the three months ended June 30, 2024, Net sales increased by 4.9% to $5,058 million, and organic sales grew by 9.0%. This growth was supported by solid performance in both the Oral, Personal and Home Care segment and the Pet Nutrition segment (Hill's Pet Nutrition). Diluted Earnings Per Share (EPS) reached $0.89, a significant increase from $0.60 in the prior year period. The company also saw an improvement in Gross profit margin to 60.6% and Operating profit margin to 21.6%, reflecting successful cost-saving initiatives and pricing strategies. The first half of 2024 also showed positive momentum with Net sales up 5.5% to $10,124 million and organic sales up 9.4%. Diluted EPS for the six months ended June 30, 2024, was $1.71, up from $1.05 in the prior year. The company continues to invest in brand building and innovation, as evidenced by increased advertising spend, positioning it for continued growth in a challenging global economic environment.

Colgate-Palmolive Company (CL) has filed an 8-K report on July 26, 2024, primarily to disclose its financial results for the quarter ended June 30, 2024. The company issued a press release on July 26, 2024, detailing these results, which is attached as an exhibit to this filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any segment-specific updates. While the 8-K itself does not provide the detailed financial figures, it serves as the official notification and incorporation by reference of the earnings announcement. Investors interested in the company's performance should consult the full press release (Exhibit 99) for comprehensive information regarding the second quarter of 2024. The filing also notes that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes and will not be incorporated into other registration statements.

Colgate-Palmolive Company (CL) filed an 8-K report on May 14, 2024, detailing the outcomes of its Annual Meeting of Stockholders held on May 10, 2024. The report indicates strong support for the company's slate of directors, with all nominated individuals elected to the board. Additionally, shareholders overwhelmingly ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the upcoming fiscal year. The company's executive compensation plan received advisory approval from stockholders, reflecting a positive sentiment towards the remuneration structure. However, a stockholder proposal advocating for an independent Board Chairman was not approved, suggesting a preference for the current governance model among a significant portion of the voting shareholders. These results provide a clear picture of shareholder sentiment on key governance and oversight matters.

Colgate-Palmolive Company reported robust financial results for the first quarter of 2024, demonstrating strong top-line growth and improved profitability. Net sales increased by 6.2% year-over-year, driven by both volume growth and significant price increases, with organic sales growing by 9.8%. This growth was broad-based across its core Oral, Personal and Home Care segment and the Pet Nutrition segment. The company also showcased enhanced profitability, with gross profit margin expanding to 60.0% from 56.9% in the prior year, attributed to higher pricing and cost savings initiatives. Operating profit saw a substantial 15% increase, reflecting improved operational efficiencies and strategic pricing actions. Diluted Earnings Per Share (EPS) rose to $0.83, up significantly from $0.45 in the first quarter of 2023, highlighting the company's ability to translate sales growth into enhanced shareholder returns. The company also announced an increase in its quarterly common stock dividend, signaling confidence in its financial health and commitment to returning value to shareholders.

Colgate-Palmolive Company (CL) has filed an 8-K report on April 26, 2024, to announce its first-quarter 2024 financial results. The core of this filing is a press release issued on the same date, which details the company's performance for the period ending March 31, 2024. Investors should refer to this press release, attached as Exhibit 99, for specific financial figures, operational updates, and management commentary regarding the quarter. While this 8-K primarily serves to incorporate the earnings press release, it is crucial for investors to examine the details within that document. This includes key financial metrics, sales performance across different segments and geographies, profitability, and any forward-looking statements or guidance provided by the company. The filing itself notes that the information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, underscoring the importance of the press release as the primary source of detailed results.

Colgate-Palmolive Company (CL) announced a significant change to its Board of Directors through an 8-K filing on February 15, 2024. The company has elected Brian Newman, the current Executive Vice President and Chief Financial Officer of United Parcel Service, Inc. (UPS), to join the Board effective March 15, 2024. Mr. Newman brings a wealth of financial and global leadership experience, particularly with 26 years at PepsiCo in various finance and operational roles, which is expected to be highly valuable to Colgate's strategic direction and oversight. This addition of new talent to the Board comes as a result of a planned retirement. Stephen I. Sadove, a current director, will retire at the end of his term and will not seek re-election at the upcoming Annual Meeting of Stockholders on May 10, 2024, in accordance with the company's mandatory director retirement policy. These board transitions are designed to ensure continued strong governance and strategic guidance for Colgate-Palmolive.

Colgate-Palmolive Company (CL) reported a solid financial performance for the fiscal year ending December 31, 2023, demonstrating resilience in a challenging global economic environment. The company achieved net sales growth of 8.5%, driven primarily by net selling price increases of 10.0%, with a slight volume decline of 0.5%. Organic sales, a key metric excluding foreign exchange, acquisitions, and divestments, also grew by a robust 8.5%, indicating underlying business strength. The Pet Nutrition segment, particularly Hill's Pet Nutrition, was a significant growth driver, with net sales increasing by 15.5% and organic sales up 10.5%. The Oral, Personal, and Home Care segment also saw net sales increase by 6.5% and organic sales by 8.0%. Despite facing increased raw and packaging material costs, the company successfully managed its gross profit margin, which improved to 58.2% from 57.0% in the prior year, aided by pricing actions and cost-saving initiatives. Diluted earnings per share (EPS) saw a notable increase to $2.77 from $2.13, reflecting improved profitability.

Colgate-Palmolive Company (CL) filed an 8-K on January 26, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The core of this filing is a press release (Exhibit 99) which provides the detailed earnings information. Investors should refer to this press release for specifics on revenue, profitability, and any forward-looking guidance the company may have issued.

Colgate-Palmolive Company (CL) filed an 8-K on October 27, 2023, primarily to report its financial results for the quarter ended September 30, 2023. The company issued a press release on October 27, 2023, which contains the details of these earnings. This filing serves as notification to investors about the company's performance during the third quarter of 2023. Investors should refer to the attached press release (Exhibit 99) for specific financial metrics, operational highlights, and management commentary regarding the company's performance. While this 8-K itself does not contain the detailed financial tables, it officially incorporates the press release by reference, making its content material for understanding CL's recent financial condition and operational results. The information provided is furnished and not deemed "filed" for certain legal purposes, which is a standard disclosure for earnings release attachments to an 8-K.

Colgate-Palmolive Company reported strong top-line growth in the third quarter of 2023, with Net sales increasing by 10.5% to $4.915 billion compared to the prior year period. This growth was driven by a significant 9.5% increase in net selling prices and a modest 0.5% volume increase, alongside a slight positive foreign exchange impact. The company's organic sales, a key non-GAAP metric excluding currency fluctuations and acquisitions, grew by 9.0%. Profitability also saw improvement, with operating profit increasing by 9% to $1.029 billion. Diluted Earnings Per Share (EPS) rose to $0.86, a notable increase from $0.74 in the prior year quarter. Despite ongoing inflationary pressures on raw materials, the company managed to expand its Gross Profit margin to 58.5% due to strategic pricing actions and cost-saving initiatives, though this was partially offset by higher input costs. The Pet Nutrition segment, driven by Hill's Pet Nutrition, showed particularly strong performance with a 21.5% increase in net sales.

Colgate-Palmolive Company (CL) has filed an 8-K report detailing an amendment to its Executive Severance Plan. The Board of Directors renewed the plan on September 13, 2023, with a primary change requiring participating executives to agree to a one-year non-compete clause following termination of employment. This amendment aims to enhance employee retention and protect the company's competitive interests. The renewed plan will have an initial term of three years, with provisions for automatic one-year extensions unless the Board decides otherwise. This offers a degree of stability for executive compensation and benefits while also introducing a stronger commitment from executives to the company's ongoing success and market position. Investors should note this update as it pertains to executive compensation and potential future executive transitions.

Colgate-Palmolive Company (CL) has filed an 8-K report on August 18, 2023, to announce a change in its Board of Directors. Michael B. Polk has resigned from his position on the Board, effective August 18, 2023, citing personal reasons for his departure. This filing is primarily informational, detailing the resignation of a director. Investors should note that while any change in board composition can be a point of interest, the stated reason for Mr. Polk's resignation is personal, and no other immediate operational or financial implications are mentioned in this specific filing. The company will continue its business operations under the current management and board structure.

Colgate-Palmolive Company (CL) filed a Current Report (8-K) on July 27, 2023, primarily to furnish a press release detailing its financial results for the quarter ended June 30, 2023. While the filing itself doesn't contain detailed financial tables, it serves as notification that the company has officially released its second-quarter earnings information to the public. Investors should refer to the attached press release (Exhibit 99) for the specific operational and financial performance metrics. The company is using this 8-K filing to comply with disclosure requirements, ensuring that material information regarding its financial condition and results of operations is made available. It is important to note that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated into other registration statements. Investors seeking detailed figures on revenue, profitability, segment performance, and forward-looking guidance must consult the referenced press release.

Colgate-Palmolive Company reported solid top-line growth in the second quarter of 2023, with Net sales increasing by 7.5% to $4.82 billion compared to the prior year. This growth was primarily driven by net selling price increases of 11.0%, though partially offset by a 1.5% decline in volume. Organic sales, excluding foreign exchange and acquisitions, rose by 8.0%. The Pet Nutrition segment, particularly Hill's Pet Nutrition, showed strong performance with a 16.0% increase in Net sales, fueled by both volume and pricing. Despite revenue growth, the company faced a significant increase in its effective income tax rate to 39.8% due to a $148 million discrete tax charge related to reassessed prior-year tax deductions. This, along with other ongoing charges, led to a decrease in net income attributable to Colgate-Palmolive Company to $502 million ($0.60 diluted EPS) from $603 million ($0.72 diluted EPS) in the prior year. Excluding certain discrete items, adjusted net income increased by 6% and adjusted diluted EPS rose by 7%, indicating underlying operational strength despite the tax impact.

This 8-K filing from Colgate-Palmolive Co. (CL) details the results of their Annual Meeting of Stockholders held on May 12, 2023. The primary focus of the report is the outcome of various shareholder votes on critical corporate governance and compensation matters. Key outcomes include the overwhelming re-election of all eleven director nominees to the Board, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and the approval of the company's executive compensation plan on a non-binding advisory basis. Shareholders also voted to continue holding advisory votes on executive compensation annually. Conversely, two stockholder proposals, one concerning an independent Board Chairman and another regarding executives retaining significant stock, did not receive majority support.

Colgate-Palmolive Company reported its first-quarter 2023 financial results, showing a notable increase in net sales, driven primarily by price increases across its product segments. While top-line growth was strong, net income and earnings per share saw a decline compared to the prior year, largely due to significant one-time charges, including a substantial accrual for an ERISA litigation matter and product recall costs. The company's Oral, Personal, and Home Care segment experienced moderate sales growth, while the Pet Nutrition segment, particularly Hill's Pet Nutrition, demonstrated robust growth in both sales and volume. Despite inflationary pressures impacting gross margins, Colgate-Palmolive is strategically managing costs and continuing to invest in advertising and innovation to support its brands and drive long-term growth.

Colgate-Palmolive Company (CL) has filed an 8-K report on April 28, 2023, to announce its financial results for the quarter ended March 31, 2023. The primary purpose of this filing is to provide investors with the company's earnings performance and financial condition through an attached press release. This report is furnished and not deemed "filed" for certain regulatory purposes, meaning it doesn't trigger liabilities under Section 18 of the Securities Exchange Act of 1934 or get automatically incorporated into future registration statements. Investors should refer to Exhibit 99, the press release dated April 28, 2023, for the specific details of the first-quarter 2023 financial results. While this 8-K filing itself does not contain the detailed financial figures, it formally incorporates the press release, which is the source of truth for the company's performance during the period. This includes key metrics such as revenue, earnings per share, and any commentary on operational performance and outlook provided by the company's management.

Colgate-Palmolive Company (CL) has announced the successful issuance and sale of $1.5 billion in aggregate principal amount of senior notes. This offering includes $500 million of 4.800% Senior Notes due 2026, $500 million of 4.600% Senior Notes due 2028, and $500 million of 4.600% Senior Notes due 2033. The issuance was conducted under the company's existing shelf registration statement and was facilitated through an underwriting agreement with several prominent financial institutions. This debt issuance represents a significant capital raising activity for Colgate-Palmolive. Investors should note the specific interest rates and maturity dates for each tranche of notes, which provide a clear picture of the company's cost of borrowing and its long-term debt obligations. The use of proceeds is not detailed in this 8-K filing, but such actions typically support general corporate purposes, potential acquisitions, or refinancing existing debt.

Colgate-Palmolive Company's 2022 10-K filing reveals a company navigating a challenging macroeconomic environment characterized by inflation and increased costs. Despite these headwinds, the company reported a 3.0% increase in Net Sales, driven by a significant 9.5% increase in selling prices, which helped offset a 2.0% decline in volume and a 4.5% negative impact from foreign exchange. Organic sales grew by 7.0%, indicating underlying brand strength. The Pet Nutrition segment, particularly Hill's Pet Nutrition, showed robust growth with a 12.0% increase in Net Sales and a 13.0% rise in organic sales, highlighting its resilience. However, the Oral, Personal, and Home Care segment experienced more modest growth and volume declines, with Europe showing flat organic sales and Asia Pacific seeing a slight decrease in net sales. The company is actively managing cost pressures through pricing actions and productivity initiatives, including the "2022 Global Productivity Initiative" aimed at reducing structural costs. Significant one-time charges, notably a $721 million pretax impairment charge related to the Filorga skin health business, impacted reported profitability. Colgate-Palmolive remains committed to shareholder returns, as evidenced by its ongoing share repurchase program and dividend increases, while also emphasizing its sustainability and DE&I strategies. The company acknowledges ongoing risks from global instability, supply chain disruptions, and evolving consumer preferences but expresses confidence in its strategy and financial position to navigate these challenges.

Colgate-Palmolive Company (CL) announced a significant addition to its Board of Directors with the election of Steven Cahillane, effective February 1, 2023. Mr. Cahillane, currently the Chairman, President, and CEO of Kellogg Company, brings a wealth of experience in global consumer products and health and nutrition industries, which is highly relevant to Colgate's business. His appointment is expected to enhance the Board's strategic oversight and guidance as the company navigates the evolving consumer landscape.

Colgate-Palmolive Company (CL) filed an 8-K on January 27, 2023, to report its financial results for the quarter and year ended December 31, 2022. The key information is disseminated via a press release, attached as Exhibit 99, which provides details on the company's performance during the period. Investors should note that the information furnished under Item 2.02 is for informational purposes and is not considered "filed" under Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated into other SEC filings.

Colgate-Palmolive Company (CL) has filed an 8-K report on January 12, 2023, detailing amendments to its Amended and Restated By-laws, effective January 12, 2023. These changes primarily focus on updating procedures for stockholder proposals, specifically concerning special meetings and director nominations. A key new requirement mandates that stockholders intending to nominate directors must disclose whether they plan to solicit proxies for at least 67% of the company's voting shares. Additionally, the by-laws have been updated to designate a Delaware state or federal court as the exclusive forum for certain legal actions against the company, including derivative suits and claims related to fiduciary duties. These amendments are largely technical and administrative, reflecting updates in line with new SEC universal proxy rules and aiming to streamline corporate governance processes. For investors, the changes mainly impact procedural aspects of engaging with the company for shareholder proposals and director nominations, as well as clarifying legal venue for specific types of lawsuits. The company has also included the full text of the amended by-laws as an exhibit for further review.

Colgate-Palmolive Company reported mixed financial results for the third quarter ended September 30, 2022. While net sales saw a slight increase of 1.0% to $4,455 million, this was primarily driven by price increases (11.5%) rather than volume growth, which declined by 4.5%. Organic sales, excluding foreign exchange, acquisitions, and divestitures, grew by a more robust 7.0%. However, profitability faced pressure, with Gross Profit declining due to significant increases in raw and packaging material costs (920 bps), partially offset by pricing and cost savings initiatives. Diluted Earnings Per Share (EPS) decreased to $0.74 from $0.75 in the prior year's quarter. The company also completed a significant acquisition in its Pet Nutrition segment, acquiring Red Collar Pet Foods for $727 million to support the growth of its Hill's Pet Nutrition business. Management highlighted ongoing challenges from global macroeconomic conditions, inflation, rising interest rates, and supply chain disruptions, while also noting efforts to mitigate these through pricing and productivity initiatives.

Colgate-Palmolive Company (CL) filed an 8-K on October 28, 2022, to report its financial results for the third quarter ended September 30, 2022. The core of this filing is the press release announcing these results, which provides investors with the company's operational and financial performance during the period. While the 8-K itself does not contain detailed financial tables, it directs investors to the attached press release for the specifics of their quarterly performance. Investors should refer to the press release (Exhibit 99) for critical details such as revenue, earnings per share, segment performance, and any forward-looking statements or guidance provided by the company. This filing serves as a formal notification of the release of these important financial updates, enabling investors to assess Colgate-Palmolive's recent business activities and financial health.

Colgate-Palmolive Company (CL) announced the completion of its public offering of $1.5 billion in senior notes across three tranches: $500 million in 3.100% Senior Notes due 2025, $500 million in 3.100% Senior Notes due 2027, and $500 million in 3.250% Senior Notes due 2032. This offering, finalized on August 9, 2022, was conducted under the company's existing shelf registration statement filed in October 2020. The issuance of these notes indicates Colgate-Palmolive's proactive approach to managing its capital structure and potentially refinancing existing debt or funding general corporate purposes. Investors can view the terms of the notes and the governing indenture, which have been filed as exhibits with the SEC, to understand the specifics of the company's debt obligations.

Colgate-Palmolive Company (CL) has announced a significant debt financing initiative through an 8-K filing on August 3, 2022. The company entered into an underwriting agreement to issue and sell a total of $1.5 billion in senior notes across three tranches: $500 million of 3.100% Senior Notes due 2025, $500 million of 3.100% Senior Notes due 2027, and $500 million of 3.250% Senior Notes due 2032. This offering represents a strategic move to raise capital, likely to fund ongoing operations, potential acquisitions, or refinance existing debt. The specific use of proceeds is not detailed in this filing, but the issuance of long-term debt signals management's confidence in the company's ability to service its obligations and manage its capital structure effectively. Investors should note the terms of these notes, including coupon rates and maturity dates, as they will impact the company's leverage and interest expense in the coming years.

Colgate-Palmolive Company (CL) filed an 8-K on July 29, 2022, to report its financial results for the quarter ended June 30, 2022. The primary purpose of this filing is to incorporate by reference the earnings press release issued on July 29, 2022. This press release contains the detailed financial performance and operational updates for the company during the second quarter of 2022. Investors should refer to the attached press release (Exhibit 99) for comprehensive information regarding Colgate-Palmolive's second-quarter performance, including revenue, profitability, and any management commentary on business trends, segment performance, and outlook. It's important to note that the information furnished under Item 2.02 is not deemed "filed" for regulatory purposes and does not carry the same liabilities as filed information, nor will it be automatically incorporated into future registration statements.